Indivior Pharmaceuticals (INDV) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Indivior Pharmaceuticals

NasdaqGS•Healthcare•Drug Manufacturers - Specialty & Generic

$34.35+0.13(<0.01%)Pre-market

Market Cap

$4.09B

P/E

11.5x

P/S

3.1x

Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders. The company's core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; and SUBOXONE Film, a buprenorphine and naloxone sublingual film. It also manufactures SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD). In addition, the company is developing INDV-2000, a selective orexin-1 receptor antagonist that is in Phase 2 clinical trial for the treatment of moderate to severe OUD; and INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc. The company was formerly known as Indivior PLC. and changed its name to Indivior Pharmaceuticals, Inc. in January 2026. Indivior Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

How this company scores

WeakMetricSide Score: 60/100

Grade capped at D — Negative equity — the balance sheet is insolvent. Strongest: Growth (19/25); weakest: Cash & Earnings Quality (12/25).

Profitability17/25

Growth19/25

Balance Sheet & Red Flags12/25

Cash & Earnings Quality12/25

Strengths

Strong marginsRising earningsInterest easily coveredCash-backed earnings

Grade capped at D

Negative equity — the balance sheet is insolvent.

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 11.5x5y range 11.5x – 27.6x

Currently below its 4-quarter median.

P/S · 3.1x5y range 1.5x – 3.6x

Currently near its 4-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

Some Concerns

Earnings Quality

Watch

FCF/Net Income has dropped below 0.7x in 3 quarters — monitor for earnings quality deterioration.

Cash Burn

Watch

FCF turned negative in 3 of the last 7 quarters — occasional cash consumption.

Price & Volume

Market Cap $4.09B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $1.33B
Q. Revenue: $343.00M
TTM EBITDA: $430.00M
TTM Op. Income: $421.00M
Q. Op. Income: $160.00M
TTM Net Income: $356.00M
Q. Net Income: $122.00M
EPS: $1.02
Shares Out.: $119.00M

$1.33B in TTM revenue grew from zero YoY, reaching $343.00M last quarter. TTM EBITDA of $430.00M and TTM operating income of $421.00M show growth is flowing through to the bottom line. TTM net income of $356.00M means revenue is converting into profit. Across the last 7 quarters, TTM revenue has risen for 2 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 85.7%
EBITDA Margin: 47.2%
Op. Margin: 46.6%
Net Margin: 35.6%

Op. margin of 46.6% is up 22.8% YoY — cost efficiency is improving. Net margin at 35.6% and gross margin of 85.7% show how much of each revenue dollar survives to profit. Across the last 7 quarters, operating margin has risen for 3 consecutive quarters — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 11.5x
P/S Ratio: 3.1x
P/B Ratio: N/A

At 11.5x P/E, the stock trades below typical market levels. P/S of 3.1x and P/B of 0.0x provide additional context. P/E sits below typical market levels while revenue is growing. Across the last 4 quarters, P/E has fallen for 3 consecutive quarters — an improving trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $1.23B
Cash: $222.00M
Long-Term Debt: $487.00M
Book Value: $-208.00M
D/E Ratio: N/A
Debt/EBITDA: 3.0

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $229.00M
TTM Free Cash Flow: $-111.00M
FCF Margin: -8.3%
FCF / Net Income: -0.3

TTM FCF of $-111.00M on $229.00M in operating cash flow. The FCF / Net Income ratio of -0.3x means the business consumes cash — it is not yet self-funding. Over the past year, free cash flow is up 0% — an improving trend.